QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)

Seagen - SGEN Stock Forecast, Price & News

$202.23
-0.79 (-0.39%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$201.59
$203.65
50-Day Range
$130.49
$203.02
52-Week Range
$105.43
$203.65
Volume
1.27 million shs
Average Volume
1.40 million shs
Market Capitalization
$37.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$188.33

Seagen MarketRank™ Forecast

Analyst Rating
Hold
2.35 Rating Score
Upside/​Downside
6.9% Downside
$188.33 Price Target
Short Interest
Healthy
0.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.34mentions of Seagen in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$24.31 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.98) to ($1.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

242nd out of 999 stocks

Biological Products, Except Diagnostic Industry

44th out of 166 stocks


SGEN stock logo

About Seagen (NASDAQ:SGEN) Stock

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also engages in the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Stock News Headlines

3 Dividend Contenders to Buy Now for Long-Term Gains Later (SGEN)
Dividend stocks have a role to play in any portfolio, and this article highlights three dividend contenders that you can buy now to get long-term gains later
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock (SGEN)
Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Seagen (NASDAQ:SGEN) Now Covered by Analysts at StockNews.com
Seagen (NASDAQ:SGEN) Stock Rating Lowered by Berenberg Bank
Seagen (NASDAQ:SGEN) PT Lowered to $129.00
Seagen (NASDAQ:SGEN) Coverage Initiated at StockNews.com
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Seagen Inc. (NASDAQ:SGEN) CMO Sells $1,998,100.00 in Stock
BMO Capital downgrades Seagen (SGEN) to a Hold
JMP Securities downgrades Seagen (SGEN) to a Hold
Pfizer Invests $43 Billion to Battle Cancer
Seagen Full Year 2022 Earnings: Beats Expectations
See More Headlines
Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Company Calendar

Last Earnings
2/15/2023
Today
3/29/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGEN
CUSIP
81257810
Employees
3,256
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$188.33
High Stock Price Forecast
$229.00
Low Stock Price Forecast
$129.00
Forecasted Upside/Downside
-6.9%
Consensus Rating
Hold
Rating Score (0-4)
2.35
Research Coverage
17 Analysts

Profitability

Net Income
$-610,310,000.00
Pretax Margin
-30.69%

Debt

Sales & Book Value

Annual Sales
$1.96 billion
Book Value
$15.10 per share

Miscellaneous

Free Float
135,796,000
Market Cap
$37.77 billion
Optionable
Optionable
Beta
0.53

Social Links


Key Executives

  • David R. Epstein
    Chief Executive Officer & Director
  • Todd E. SimpsonTodd E. Simpson
    Chief Financial Officer
  • Vaughn B. HimesVaughn B. Himes
    Chief Technical Officer
  • Roger D. DanseyRoger D. Dansey
    Chief Medical Officer
  • Guy Padbury
    Senior Vice President, Translational Sciences













SGEN Stock - Frequently Asked Questions

Should I buy or sell Seagen stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings
or view top-rated stocks.

What is Seagen's stock price forecast for 2023?

17 equities research analysts have issued twelve-month price targets for Seagen's stock. Their SGEN share price forecasts range from $129.00 to $229.00. On average, they expect the company's share price to reach $188.33 in the next twelve months. This suggests that the stock has a possible downside of 6.9%.
View analysts price targets for SGEN
or view top-rated stocks among Wall Street analysts.

How have SGEN shares performed in 2023?

Seagen's stock was trading at $128.51 at the beginning of the year. Since then, SGEN shares have increased by 57.4% and is now trading at $202.23.
View the best growth stocks for 2023 here
.

Are investors shorting Seagen?

Seagen saw a decline in short interest in March. As of March 15th, there was short interest totaling 1,820,000 shares, a decline of 44.7% from the February 28th total of 3,290,000 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is currently 1.4 days.
View Seagen's Short Interest
.

When is Seagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our SGEN earnings forecast
.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) posted its quarterly earnings results on Wednesday, February, 15th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.22. The biotechnology company had revenue of $528.20 million for the quarter, compared to analysts' expectations of $479.81 million. Seagen had a negative net margin of 31.10% and a negative trailing twelve-month return on equity of 21.13%. The business's revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.95) EPS.

What guidance has Seagen issued on next quarter's earnings?

Seagen updated its FY 2023 earnings guidance on Wednesday, February, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.14 billion-$2.24 billion, compared to the consensus revenue estimate of $2.30 billion.

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by many different retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (1.76%), Norges Bank (1.18%), Geode Capital Management LLC (1.03%), Avoro Capital Advisors LLC (1.02%), Franklin Resources Inc. (0.94%) and T. Rowe Price Investment Management Inc. (0.87%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends
.

How do I buy shares of Seagen?

Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $202.23.

How much money does Seagen make?

Seagen (NASDAQ:SGEN) has a market capitalization of $37.77 billion and generates $1.96 billion in revenue each year. The biotechnology company earns $-610,310,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis.

How many employees does Seagen have?

The company employs 3,256 workers across the globe.

Does Seagen have any subsidiaries?
The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001.

This page (NASDAQ:SGEN) was last updated on 3/29/2023 by MarketBeat.com Staff